Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO Mice: Comparison of intramuscular and intravenous administration

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 3, 2011, Pages 325-333

  Cimmino, Giovanni ^a   Giannarelli, Chiara ^a   Chen, Wei ^a   Alique, Matilde ^a   Santos Gallego, Carlos G ^a   Fuster, Valentin ^a   Hajjar, Roger J ^a   Walsh, Christopher E ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoprotein A I; atherosclerosis; gene transfer; HDL lipoproteins

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARVOVIRUS VECTOR; SCAVENGER RECEPTOR BI;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART; LIVER; MACROPHAGE; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, HDL; DEPENDOVIRUS; DIET, ATHEROGENIC; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; LIVER; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; SCAVENGER RECEPTORS, CLASS B; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 79952816158     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182092841     Document Type: Article

References (42)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
2. Hausenloy DJ, Yellon DM Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706-714. (Pubitemid 351744686)
3. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation. 2006;113: 1140-1150.
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am JMed. 1977;62:707-714. (Pubitemid 8110784)
5. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-2838. (Pubitemid 17178361)
6. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592. (Pubitemid 33126837)
7. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-1591 (Pubitemid 32240250)
8. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. JAm Coll Cardiol. 2008; 51:2199-2211. (Pubitemid 351754991)
9. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets. 2008;9:196-203. (Pubitemid 351843600)
10. Santos-Gallego CG, Ibanez B, Badimon JJ. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem Pharmacol. 2008; 76:443-452.
11. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest. 1990;85:1234-1241. (Pubitemid 20123768)
12. Corti R, Osende J, Hutter R, et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis. 2007;190:106-113. (Pubitemid 44908325)
13. Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. JAm Coll Cardiol. 2008;51: 1104-1109. (Pubitemid 351374767)
14. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300. (Pubitemid 37430562)
15. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlledtrial. JAMA. 2007;297:1675-1682. (Pubitemid 46631626)
16. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232. (Pubitemid 40962099)
17. Kaul S, Coin B, Hedayiti A, et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol. 2004;44:1311-1319. (Pubitemid 39208891)
18. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. JAm Coll Cardiol. 2008;51:1098-1103. (Pubitemid 351374769)
19. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. JAm Coll Cardiol. 2010;55:2721-2726.
20. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. JAm Coll Cardiol. 2010;55:2727-2735.
21. Kitajima K, Marchadier DH, Burstein H, et al. Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis. 2006;186:65-73.
22. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583-593.
23. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008;15:858-863. (Pubitemid 351712619)
24. Van Linthout S, Spillmann F, Riad A, et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy Circulation. 2008;117:1563-1573. (Pubitemid 351444665)
25. Lebherz C, Sanmiguel J, Wilson JM, et al. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007;6:15.
26. Vaessen SF, Veldman RJ, Comijn EM, et al. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency J Gene Med. 2009;11:697-707.
27. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol. 2005;79: 214-224. (Pubitemid 39650967)
28. Vandendriessche T, Thorrez L, Acosta-Sanchez A et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy J Thromb Haemost. 2007;5:16-24. (Pubitemid 44921062)
29. Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med. 2005;7:442-451. (Pubitemid 40553125)
30. Ohshima S, Shin JH, Yuasa K, et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther. 2009;17:73-80.
31. Cimmino G, Chen W, Speidl WS, et al. Safe and sustained overexpression of functional apolipoprotein A-I/high-density lipoprotein in apolipopro-tein A-I-null mice by muscular adeno-associated viral serotype 8 vector gene transfer. J Cardiovasc Pharmacol. 2009;54:405-411.
32. De Geest B, Van Linthout S, Collen D. Sustained expression of human apo A-I following adenoviral gene transfer in mice. Gene Ther. 2001;8: 121-127. (Pubitemid 32162425)
33. Paigen B, Morrow A, Holmes PA, et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240. (Pubitemid 17159775)
34. Groot PH, van Vlijmen BJ, Benson GM, et al. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol. 1996;16:926-933. (Pubitemid 26266889)
35. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517. (Pubitemid 39612564)
36. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243-2250. (Pubitemid 44789989)
37. Cimmino G, Ibanez B, Vilahur G, et al. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). J Cell Mol Med. 2009;13:3226-3235.
38. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335. (Pubitemid 26372454)
39. Feng Y Van Craeyveld E, Jacobs F, et al. Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. JMol Med. 2009;87:287-297.
40. Feng Y van Eck M, Van Craeyveld E, et al. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood. 2009;113:755-764.
41. Feng Y Jacobs F, Van Craeyveld E, et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28:278-283.
42. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23: 321-328. (Pubitemid 41094420)